Gloftrinid

Gloftrinid is a prescription injectable medication that contains the active ingredient bortezomib. It is supplied as a sterile solution for intravenous or subcutaneous administration. The product is marketed in the European Union and belongs to the proteasome inhibitor class, used as an antineoplastic agent for certain blood cancers. Its formulation enables reversible inhibition of the 26S proteasome, leading to apoptosis of malignant cells.

Gloftrinid is indicated for the treatment of specific hematologic malignancies and is administered under the supervision of a qualified healthcare professional.

- Treatment of newly diagnosed multiple myeloma in combination with other anti‑myeloma agents. - Therapy for relapsed or refractory multiple myeloma. - Management of mantle cell lymphoma, either as initial therapy or after disease progression. - Use as part of a multi‑drug regimen in clinical trials for other proteasome‑sensitive cancers. - May be considered for off‑label investigational use in selected proteasome‑dependent malignancies under strict clinical oversight.

Side effects of Gloftrinid vary in frequency and severity. Patients should be monitored regularly for both common and serious adverse reactions.

Common: - Fatigue or generalized weakness. - Peripheral neuropathy, often presenting as tingling or numbness in the hands or feet. - Nausea, vomiting, or loss of appetite. - Diarrhea or constipation. - Low blood cell counts (anemia, neutropenia, thrombocytopenia). - Mild fever or flu‑like symptoms.

Serious: - Severe peripheral neuropathy that interferes with daily activities. - Significant infections due to immune suppression. - Pulmonary complications such as dyspnea or interstitial lung disease. - Cardiac events including arrhythmias or heart failure. - Hepatic dysfunction indicated by elevated liver enzymes. - Severe hypersensitivity reactions, including anaphylaxis.

Gloftrinid requires careful patient assessment and ongoing monitoring to minimize risks.

- Perform baseline and periodic complete blood counts to detect cytopenias. - Assess peripheral nerve function before each dose and adjust treatment if neuropathy worsens. - Monitor liver function tests regularly, especially in patients with pre‑existing hepatic disease. - Evaluate cardiac status in patients with known heart disease or risk factors. - Use caution in pregnant or breastfeeding women; discuss potential risks and benefits. - Avoid administration in patients with active uncontrolled infections. - Ensure proper injection technique to reduce injection‑site reactions.

Gloftrinid may interact with other medications, affecting its safety or efficacy.

Avoid: - Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase bortezomib exposure. - Live vaccines during treatment due to immunosuppression. - Other proteasome inhibitors, which could compound toxicity.

Use with caution: - Anticoagulants, as thrombocytopenia may increase bleeding risk. - Immunosuppressive agents (e.g., corticosteroids, azathioprine) that may heighten infection risk. - Drugs that cause peripheral neuropathy (e.g., vincristine, taxanes) may exacerbate nerve damage. - Medications affecting hepatic metabolism, requiring dose adjustments based on liver function.